0001209191-21-046031.txt : 20210708
0001209191-21-046031.hdr.sgml : 20210708
20210708181823
ACCESSION NUMBER: 0001209191-21-046031
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210706
FILED AS OF DATE: 20210708
DATE AS OF CHANGE: 20210708
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zuga Matt
CENTRAL INDEX KEY: 0001790214
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40551
FILM NUMBER: 211081209
MAIL ADDRESS:
STREET 1: C/O TELA BIO, INC.
STREET 2: 1 GREAT VALLEY PARKWAY, SUITE 24
CITY: MALVERN
STATE: PA
ZIP: 19355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Acumen Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001576885
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 364108129
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4435 NORTH FIRST STREET, SUITE 360
CITY: LIVERMORE
STATE: CA
ZIP: 94551
BUSINESS PHONE: 925-368-8508
MAIL ADDRESS:
STREET 1: 4435 NORTH FIRST STREET, SUITE 360
CITY: LIVERMORE
STATE: CA
ZIP: 94551
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-07-06
0
0001576885
Acumen Pharmaceuticals, Inc.
ABOS
0001790214
Zuga Matt
C/O ACUMEN PHARMACEUTICALS, INC.
427 PARK STREET
CHARLOTTESVILLE
VA
22902
0
1
0
0
Chief Financial Officer
Common Stock
2021-07-06
4
C
0
26187
A
26187
D
Series A-1 Preferred Stock
2021-07-06
4
C
0
15659
D
Common Stock
15659
15659
D
Series B Preferred Stock
2021-07-06
4
C
0
10528
D
Common Stock
10528
10528
D
On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred
Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of
the Issuer's common stock. The shares had no expiration date.
/s/ Katherine Denby, Attorney-in-Fact
2021-07-08